nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—SLC7A5—Desoximetasone—Methylprednisolone—psoriatic arthritis	0.00714	0.174	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Dexamethasone—psoriatic arthritis	0.00703	0.172	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Betamethasone—psoriatic arthritis	0.00703	0.172	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Triamcinolone—psoriatic arthritis	0.00686	0.168	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Prednisone—psoriatic arthritis	0.00651	0.159	CbGdCrCtD
L-DOPA—SLC7A5—Desoximetasone—Prednisolone—psoriatic arthritis	0.00636	0.155	CbGdCrCtD
L-DOPA—Myocardial infarction—Prednisone—psoriatic arthritis	0.00237	0.00247	CcSEcCtD
L-DOPA—Neuropathy peripheral—Prednisone—psoriatic arthritis	0.00237	0.00247	CcSEcCtD
L-DOPA—Malaise—Prednisolone—psoriatic arthritis	0.00234	0.00244	CcSEcCtD
L-DOPA—Dysgeusia—Triamcinolone—psoriatic arthritis	0.00234	0.00244	CcSEcCtD
L-DOPA—Syncope—Prednisolone—psoriatic arthritis	0.00233	0.00243	CcSEcCtD
L-DOPA—Back pain—Triamcinolone—psoriatic arthritis	0.00231	0.00241	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisolone—psoriatic arthritis	0.00228	0.00238	CcSEcCtD
L-DOPA—Convulsion—Prednisolone—psoriatic arthritis	0.00225	0.00235	CcSEcCtD
L-DOPA—Hypertension—Prednisolone—psoriatic arthritis	0.00224	0.00234	CcSEcCtD
L-DOPA—Arrhythmia—Betamethasone—psoriatic arthritis	0.00222	0.00232	CcSEcCtD
L-DOPA—Arrhythmia—Dexamethasone—psoriatic arthritis	0.00222	0.00232	CcSEcCtD
L-DOPA—Ill-defined disorder—Triamcinolone—psoriatic arthritis	0.00222	0.00231	CcSEcCtD
L-DOPA—Ill-defined disorder—Methylprednisolone—psoriatic arthritis	0.00221	0.00231	CcSEcCtD
L-DOPA—Alopecia—Betamethasone—psoriatic arthritis	0.0022	0.00229	CcSEcCtD
L-DOPA—Alopecia—Dexamethasone—psoriatic arthritis	0.0022	0.00229	CcSEcCtD
L-DOPA—Discomfort—Prednisolone—psoriatic arthritis	0.00218	0.00228	CcSEcCtD
L-DOPA—Angioedema—Triamcinolone—psoriatic arthritis	0.00218	0.00228	CcSEcCtD
L-DOPA—Haemoglobin—Prednisone—psoriatic arthritis	0.00218	0.00227	CcSEcCtD
L-DOPA—Angioedema—Methylprednisolone—psoriatic arthritis	0.00218	0.00227	CcSEcCtD
L-DOPA—Haemorrhage—Prednisone—psoriatic arthritis	0.00217	0.00226	CcSEcCtD
L-DOPA—Hallucination—Prednisone—psoriatic arthritis	0.00216	0.00225	CcSEcCtD
L-DOPA—Malaise—Triamcinolone—psoriatic arthritis	0.00215	0.00225	CcSEcCtD
L-DOPA—Malaise—Methylprednisolone—psoriatic arthritis	0.00215	0.00224	CcSEcCtD
L-DOPA—Syncope—Triamcinolone—psoriatic arthritis	0.00214	0.00223	CcSEcCtD
L-DOPA—Syncope—Methylprednisolone—psoriatic arthritis	0.00214	0.00223	CcSEcCtD
L-DOPA—Oedema—Prednisolone—psoriatic arthritis	0.00212	0.00221	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Methotrexate—psoriatic arthritis	0.0021	0.00219	CcSEcCtD
L-DOPA—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.0021	0.00219	CcSEcCtD
L-DOPA—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.00209	0.00218	CcSEcCtD
L-DOPA—Shock—Prednisolone—psoriatic arthritis	0.00209	0.00217	CcSEcCtD
L-DOPA—Cough—Triamcinolone—psoriatic arthritis	0.00208	0.00217	CcSEcCtD
L-DOPA—Convulsion—Triamcinolone—psoriatic arthritis	0.00207	0.00216	CcSEcCtD
L-DOPA—Convulsion—Methylprednisolone—psoriatic arthritis	0.00206	0.00215	CcSEcCtD
L-DOPA—Hypertension—Triamcinolone—psoriatic arthritis	0.00206	0.00215	CcSEcCtD
L-DOPA—Hypertension—Methylprednisolone—psoriatic arthritis	0.00206	0.00214	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00205	0.00214	CcSEcCtD
L-DOPA—Anxiety—Methylprednisolone—psoriatic arthritis	0.00202	0.00211	CcSEcCtD
L-DOPA—Depression—Methotrexate—psoriatic arthritis	0.00201	0.0021	CcSEcCtD
L-DOPA—Flushing—Prednisone—psoriatic arthritis	0.00201	0.0021	CcSEcCtD
L-DOPA—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.00201	0.0021	CcSEcCtD
L-DOPA—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.00201	0.0021	CcSEcCtD
L-DOPA—Discomfort—Triamcinolone—psoriatic arthritis	0.00201	0.00209	CcSEcCtD
L-DOPA—Discomfort—Methylprednisolone—psoriatic arthritis	0.002	0.00209	CcSEcCtD
L-DOPA—Dry mouth—Triamcinolone—psoriatic arthritis	0.00199	0.00207	CcSEcCtD
L-DOPA—Angioedema—Betamethasone—psoriatic arthritis	0.00198	0.00206	CcSEcCtD
L-DOPA—Angioedema—Dexamethasone—psoriatic arthritis	0.00198	0.00206	CcSEcCtD
L-DOPA—Confusional state—Methylprednisolone—psoriatic arthritis	0.00196	0.00204	CcSEcCtD
L-DOPA—Malaise—Betamethasone—psoriatic arthritis	0.00195	0.00204	CcSEcCtD
L-DOPA—Malaise—Dexamethasone—psoriatic arthritis	0.00195	0.00204	CcSEcCtD
L-DOPA—Oedema—Triamcinolone—psoriatic arthritis	0.00195	0.00203	CcSEcCtD
L-DOPA—Syncope—Dexamethasone—psoriatic arthritis	0.00194	0.00203	CcSEcCtD
L-DOPA—Syncope—Betamethasone—psoriatic arthritis	0.00194	0.00203	CcSEcCtD
L-DOPA—Arrhythmia—Prednisone—psoriatic arthritis	0.00194	0.00202	CcSEcCtD
L-DOPA—Shock—Triamcinolone—psoriatic arthritis	0.00192	0.002	CcSEcCtD
L-DOPA—Insomnia—Prednisolone—psoriatic arthritis	0.00192	0.002	CcSEcCtD
L-DOPA—Alopecia—Prednisone—psoriatic arthritis	0.00192	0.002	CcSEcCtD
L-DOPA—Shock—Methylprednisolone—psoriatic arthritis	0.00191	0.00199	CcSEcCtD
L-DOPA—Loss of consciousness—Betamethasone—psoriatic arthritis	0.0019	0.00199	CcSEcCtD
L-DOPA—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.0019	0.00199	CcSEcCtD
L-DOPA—Paraesthesia—Prednisolone—psoriatic arthritis	0.0019	0.00198	CcSEcCtD
L-DOPA—Mental disorder—Prednisone—psoriatic arthritis	0.0019	0.00198	CcSEcCtD
L-DOPA—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00188	0.00196	CcSEcCtD
L-DOPA—Agranulocytosis—Methotrexate—psoriatic arthritis	0.00188	0.00196	CcSEcCtD
L-DOPA—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00188	0.00196	CcSEcCtD
L-DOPA—Convulsion—Dexamethasone—psoriatic arthritis	0.00188	0.00196	CcSEcCtD
L-DOPA—Convulsion—Betamethasone—psoriatic arthritis	0.00188	0.00196	CcSEcCtD
L-DOPA—Hypertension—Dexamethasone—psoriatic arthritis	0.00187	0.00195	CcSEcCtD
L-DOPA—Hypertension—Betamethasone—psoriatic arthritis	0.00187	0.00195	CcSEcCtD
L-DOPA—Anxiety—Dexamethasone—psoriatic arthritis	0.00184	0.00192	CcSEcCtD
L-DOPA—Anxiety—Betamethasone—psoriatic arthritis	0.00184	0.00192	CcSEcCtD
L-DOPA—Discomfort—Dexamethasone—psoriatic arthritis	0.00182	0.0019	CcSEcCtD
L-DOPA—Discomfort—Betamethasone—psoriatic arthritis	0.00182	0.0019	CcSEcCtD
L-DOPA—Haemoglobin—Methotrexate—psoriatic arthritis	0.00182	0.0019	CcSEcCtD
L-DOPA—Hypotension—Methylprednisolone—psoriatic arthritis	0.00182	0.00189	CcSEcCtD
L-DOPA—Pain—Prednisolone—psoriatic arthritis	0.00181	0.00189	CcSEcCtD
L-DOPA—Haemorrhage—Methotrexate—psoriatic arthritis	0.00181	0.00189	CcSEcCtD
L-DOPA—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00179	0.00187	CcSEcCtD
L-DOPA—Vision blurred—Prednisone—psoriatic arthritis	0.00178	0.00185	CcSEcCtD
L-DOPA—Urethral disorder—Methotrexate—psoriatic arthritis	0.00178	0.00185	CcSEcCtD
L-DOPA—Oedema—Dexamethasone—psoriatic arthritis	0.00177	0.00184	CcSEcCtD
L-DOPA—Oedema—Betamethasone—psoriatic arthritis	0.00177	0.00184	CcSEcCtD
L-DOPA—Insomnia—Triamcinolone—psoriatic arthritis	0.00176	0.00184	CcSEcCtD
L-DOPA—Insomnia—Methylprednisolone—psoriatic arthritis	0.00176	0.00183	CcSEcCtD
L-DOPA—Ill-defined disorder—Prednisone—psoriatic arthritis	0.00175	0.00183	CcSEcCtD
L-DOPA—Paraesthesia—Triamcinolone—psoriatic arthritis	0.00175	0.00182	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisolone—psoriatic arthritis	0.00175	0.00182	CcSEcCtD
L-DOPA—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.00175	0.00182	CcSEcCtD
L-DOPA—Anaemia—Prednisone—psoriatic arthritis	0.00174	0.00182	CcSEcCtD
L-DOPA—Shock—Betamethasone—psoriatic arthritis	0.00174	0.00181	CcSEcCtD
L-DOPA—Shock—Dexamethasone—psoriatic arthritis	0.00174	0.00181	CcSEcCtD
L-DOPA—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00174	0.00181	CcSEcCtD
L-DOPA—Agitation—Prednisone—psoriatic arthritis	0.00173	0.00181	CcSEcCtD
L-DOPA—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.00173	0.00181	CcSEcCtD
L-DOPA—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.00173	0.00181	CcSEcCtD
L-DOPA—Angioedema—Prednisone—psoriatic arthritis	0.00172	0.0018	CcSEcCtD
L-DOPA—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00172	0.00179	CcSEcCtD
L-DOPA—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00171	0.00178	CcSEcCtD
L-DOPA—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00171	0.00178	CcSEcCtD
L-DOPA—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00171	0.00178	CcSEcCtD
L-DOPA—Malaise—Prednisone—psoriatic arthritis	0.0017	0.00177	CcSEcCtD
L-DOPA—Syncope—Prednisone—psoriatic arthritis	0.00169	0.00176	CcSEcCtD
L-DOPA—Anorexia—Betamethasone—psoriatic arthritis	0.00169	0.00176	CcSEcCtD
L-DOPA—Anorexia—Dexamethasone—psoriatic arthritis	0.00169	0.00176	CcSEcCtD
L-DOPA—Urticaria—Prednisolone—psoriatic arthritis	0.00168	0.00176	CcSEcCtD
L-DOPA—Fatigue—Triamcinolone—psoriatic arthritis	0.00168	0.00175	CcSEcCtD
L-DOPA—Fatigue—Methylprednisolone—psoriatic arthritis	0.00168	0.00175	CcSEcCtD
L-DOPA—Pain—Triamcinolone—psoriatic arthritis	0.00167	0.00174	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisone—psoriatic arthritis	0.00166	0.00173	CcSEcCtD
L-DOPA—Hypotension—Betamethasone—psoriatic arthritis	0.00165	0.00172	CcSEcCtD
L-DOPA—Hypotension—Dexamethasone—psoriatic arthritis	0.00165	0.00172	CcSEcCtD
L-DOPA—Convulsion—Prednisone—psoriatic arthritis	0.00163	0.0017	CcSEcCtD
L-DOPA—Hypertension—Prednisone—psoriatic arthritis	0.00163	0.0017	CcSEcCtD
L-DOPA—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.00161	0.00167	CcSEcCtD
L-DOPA—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.0016	0.00167	CcSEcCtD
L-DOPA—Anxiety—Prednisone—psoriatic arthritis	0.0016	0.00167	CcSEcCtD
L-DOPA—Alopecia—Methotrexate—psoriatic arthritis	0.0016	0.00167	CcSEcCtD
L-DOPA—Insomnia—Betamethasone—psoriatic arthritis	0.0016	0.00167	CcSEcCtD
L-DOPA—Insomnia—Dexamethasone—psoriatic arthritis	0.0016	0.00167	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.00159	0.00166	CcSEcCtD
L-DOPA—Paraesthesia—Betamethasone—psoriatic arthritis	0.00159	0.00166	CcSEcCtD
L-DOPA—Paraesthesia—Dexamethasone—psoriatic arthritis	0.00159	0.00166	CcSEcCtD
L-DOPA—Discomfort—Prednisone—psoriatic arthritis	0.00159	0.00165	CcSEcCtD
L-DOPA—Mental disorder—Methotrexate—psoriatic arthritis	0.00159	0.00165	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00156	0.00163	CcSEcCtD
L-DOPA—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00156	0.00162	CcSEcCtD
L-DOPA—Dyspepsia—Betamethasone—psoriatic arthritis	0.00156	0.00162	CcSEcCtD
L-DOPA—Urticaria—Triamcinolone—psoriatic arthritis	0.00155	0.00161	CcSEcCtD
L-DOPA—Urticaria—Methylprednisolone—psoriatic arthritis	0.00154	0.00161	CcSEcCtD
L-DOPA—Dysgeusia—Methotrexate—psoriatic arthritis	0.00154	0.00161	CcSEcCtD
L-DOPA—Oedema—Prednisone—psoriatic arthritis	0.00154	0.00161	CcSEcCtD
L-DOPA—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00154	0.0016	CcSEcCtD
L-DOPA—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00154	0.0016	CcSEcCtD
L-DOPA—Decreased appetite—Betamethasone—psoriatic arthritis	0.00154	0.0016	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00153	0.00159	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00153	0.00159	CcSEcCtD
L-DOPA—Back pain—Methotrexate—psoriatic arthritis	0.00153	0.00159	CcSEcCtD
L-DOPA—Fatigue—Dexamethasone—psoriatic arthritis	0.00152	0.00159	CcSEcCtD
L-DOPA—Fatigue—Betamethasone—psoriatic arthritis	0.00152	0.00159	CcSEcCtD
L-DOPA—Shock—Prednisone—psoriatic arthritis	0.00152	0.00158	CcSEcCtD
L-DOPA—Pain—Betamethasone—psoriatic arthritis	0.00151	0.00158	CcSEcCtD
L-DOPA—Pain—Dexamethasone—psoriatic arthritis	0.00151	0.00158	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00149	0.00155	CcSEcCtD
L-DOPA—Vision blurred—Methotrexate—psoriatic arthritis	0.00149	0.00155	CcSEcCtD
L-DOPA—Anorexia—Prednisone—psoriatic arthritis	0.00147	0.00153	CcSEcCtD
L-DOPA—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.00146	0.00153	CcSEcCtD
L-DOPA—Anaemia—Methotrexate—psoriatic arthritis	0.00146	0.00152	CcSEcCtD
L-DOPA—Feeling abnormal—Betamethasone—psoriatic arthritis	0.00146	0.00152	CcSEcCtD
L-DOPA—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.00146	0.00152	CcSEcCtD
L-DOPA—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00145	0.00151	CcSEcCtD
L-DOPA—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00145	0.00151	CcSEcCtD
L-DOPA—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00144	0.0015	CcSEcCtD
L-DOPA—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00143	0.00149	CcSEcCtD
L-DOPA—Malaise—Methotrexate—psoriatic arthritis	0.00142	0.00148	CcSEcCtD
L-DOPA—Leukopenia—Methotrexate—psoriatic arthritis	0.00141	0.00147	CcSEcCtD
L-DOPA—Urticaria—Betamethasone—psoriatic arthritis	0.0014	0.00146	CcSEcCtD
L-DOPA—Urticaria—Dexamethasone—psoriatic arthritis	0.0014	0.00146	CcSEcCtD
L-DOPA—Dizziness—Prednisolone—psoriatic arthritis	0.0014	0.00146	CcSEcCtD
L-DOPA—Asthenia—Triamcinolone—psoriatic arthritis	0.0014	0.00146	CcSEcCtD
L-DOPA—Abdominal pain—Dexamethasone—psoriatic arthritis	0.0014	0.00146	CcSEcCtD
L-DOPA—Abdominal pain—Betamethasone—psoriatic arthritis	0.0014	0.00146	CcSEcCtD
L-DOPA—Asthenia—Methylprednisolone—psoriatic arthritis	0.0014	0.00145	CcSEcCtD
L-DOPA—Insomnia—Prednisone—psoriatic arthritis	0.00139	0.00145	CcSEcCtD
L-DOPA—Paraesthesia—Prednisone—psoriatic arthritis	0.00138	0.00144	CcSEcCtD
L-DOPA—Pruritus—Triamcinolone—psoriatic arthritis	0.00138	0.00144	CcSEcCtD
L-DOPA—Cough—Methotrexate—psoriatic arthritis	0.00138	0.00143	CcSEcCtD
L-DOPA—Pruritus—Methylprednisolone—psoriatic arthritis	0.00138	0.00143	CcSEcCtD
L-DOPA—Convulsion—Methotrexate—psoriatic arthritis	0.00137	0.00142	CcSEcCtD
L-DOPA—Dyspepsia—Prednisone—psoriatic arthritis	0.00136	0.00141	CcSEcCtD
L-DOPA—Chest pain—Methotrexate—psoriatic arthritis	0.00134	0.0014	CcSEcCtD
L-DOPA—Decreased appetite—Prednisone—psoriatic arthritis	0.00134	0.0014	CcSEcCtD
L-DOPA—Rash—Prednisolone—psoriatic arthritis	0.00134	0.00139	CcSEcCtD
L-DOPA—Dermatitis—Prednisolone—psoriatic arthritis	0.00133	0.00139	CcSEcCtD
L-DOPA—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00133	0.00139	CcSEcCtD
L-DOPA—Fatigue—Prednisone—psoriatic arthritis	0.00133	0.00138	CcSEcCtD
L-DOPA—Headache—Prednisolone—psoriatic arthritis	0.00133	0.00138	CcSEcCtD
L-DOPA—Discomfort—Methotrexate—psoriatic arthritis	0.00133	0.00138	CcSEcCtD
L-DOPA—Constipation—Prednisone—psoriatic arthritis	0.00132	0.00137	CcSEcCtD
L-DOPA—Confusional state—Methotrexate—psoriatic arthritis	0.0013	0.00135	CcSEcCtD
L-DOPA—Dizziness—Triamcinolone—psoriatic arthritis	0.00129	0.00134	CcSEcCtD
L-DOPA—Dizziness—Methylprednisolone—psoriatic arthritis	0.00129	0.00134	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisone—psoriatic arthritis	0.00127	0.00132	CcSEcCtD
L-DOPA—Asthenia—Betamethasone—psoriatic arthritis	0.00127	0.00132	CcSEcCtD
L-DOPA—Asthenia—Dexamethasone—psoriatic arthritis	0.00127	0.00132	CcSEcCtD
L-DOPA—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.00126	0.00131	CcSEcCtD
L-DOPA—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.00126	0.00131	CcSEcCtD
L-DOPA—Nausea—Prednisolone—psoriatic arthritis	0.00126	0.00131	CcSEcCtD
L-DOPA—Pruritus—Betamethasone—psoriatic arthritis	0.00125	0.0013	CcSEcCtD
L-DOPA—Pruritus—Dexamethasone—psoriatic arthritis	0.00125	0.0013	CcSEcCtD
L-DOPA—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00124	0.0013	CcSEcCtD
L-DOPA—Vomiting—Triamcinolone—psoriatic arthritis	0.00124	0.00129	CcSEcCtD
L-DOPA—Vomiting—Methylprednisolone—psoriatic arthritis	0.00124	0.00129	CcSEcCtD
L-DOPA—Rash—Triamcinolone—psoriatic arthritis	0.00123	0.00128	CcSEcCtD
L-DOPA—Dermatitis—Triamcinolone—psoriatic arthritis	0.00123	0.00128	CcSEcCtD
L-DOPA—Anorexia—Methotrexate—psoriatic arthritis	0.00123	0.00128	CcSEcCtD
L-DOPA—Rash—Methylprednisolone—psoriatic arthritis	0.00123	0.00128	CcSEcCtD
L-DOPA—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00122	0.00128	CcSEcCtD
L-DOPA—Urticaria—Prednisone—psoriatic arthritis	0.00122	0.00128	CcSEcCtD
L-DOPA—Headache—Triamcinolone—psoriatic arthritis	0.00122	0.00127	CcSEcCtD
L-DOPA—Headache—Methylprednisolone—psoriatic arthritis	0.00122	0.00127	CcSEcCtD
L-DOPA—Abdominal pain—Prednisone—psoriatic arthritis	0.00122	0.00127	CcSEcCtD
L-DOPA—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00121	0.00126	CcSEcCtD
L-DOPA—Diarrhoea—Betamethasone—psoriatic arthritis	0.00121	0.00126	CcSEcCtD
L-DOPA—Hypotension—Methotrexate—psoriatic arthritis	0.0012	0.00125	CcSEcCtD
L-DOPA—Dizziness—Betamethasone—psoriatic arthritis	0.00117	0.00122	CcSEcCtD
L-DOPA—Dizziness—Dexamethasone—psoriatic arthritis	0.00117	0.00122	CcSEcCtD
L-DOPA—Insomnia—Methotrexate—psoriatic arthritis	0.00116	0.00121	CcSEcCtD
L-DOPA—Nausea—Triamcinolone—psoriatic arthritis	0.00116	0.00121	CcSEcCtD
L-DOPA—Paraesthesia—Methotrexate—psoriatic arthritis	0.00116	0.0012	CcSEcCtD
L-DOPA—Nausea—Methylprednisolone—psoriatic arthritis	0.00116	0.0012	CcSEcCtD
L-DOPA—Dyspnoea—Methotrexate—psoriatic arthritis	0.00115	0.0012	CcSEcCtD
L-DOPA—Somnolence—Methotrexate—psoriatic arthritis	0.00114	0.00119	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisone—psoriatic arthritis	0.00113	0.00118	CcSEcCtD
L-DOPA—Dyspepsia—Methotrexate—psoriatic arthritis	0.00113	0.00118	CcSEcCtD
L-DOPA—Vomiting—Betamethasone—psoriatic arthritis	0.00112	0.00117	CcSEcCtD
L-DOPA—Vomiting—Dexamethasone—psoriatic arthritis	0.00112	0.00117	CcSEcCtD
L-DOPA—Decreased appetite—Methotrexate—psoriatic arthritis	0.00112	0.00117	CcSEcCtD
L-DOPA—Rash—Dexamethasone—psoriatic arthritis	0.00111	0.00116	CcSEcCtD
L-DOPA—Rash—Betamethasone—psoriatic arthritis	0.00111	0.00116	CcSEcCtD
L-DOPA—Dermatitis—Betamethasone—psoriatic arthritis	0.00111	0.00116	CcSEcCtD
L-DOPA—Dermatitis—Dexamethasone—psoriatic arthritis	0.00111	0.00116	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00111	0.00116	CcSEcCtD
L-DOPA—Fatigue—Methotrexate—psoriatic arthritis	0.00111	0.00116	CcSEcCtD
L-DOPA—Headache—Betamethasone—psoriatic arthritis	0.00111	0.00116	CcSEcCtD
L-DOPA—Headache—Dexamethasone—psoriatic arthritis	0.00111	0.00116	CcSEcCtD
L-DOPA—Asthenia—Prednisone—psoriatic arthritis	0.0011	0.00115	CcSEcCtD
L-DOPA—Pain—Methotrexate—psoriatic arthritis	0.0011	0.00115	CcSEcCtD
L-DOPA—Pruritus—Prednisone—psoriatic arthritis	0.00109	0.00114	CcSEcCtD
L-DOPA—Feeling abnormal—Methotrexate—psoriatic arthritis	0.00106	0.00111	CcSEcCtD
L-DOPA—Diarrhoea—Prednisone—psoriatic arthritis	0.00105	0.0011	CcSEcCtD
L-DOPA—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00105	0.0011	CcSEcCtD
L-DOPA—Nausea—Betamethasone—psoriatic arthritis	0.00105	0.0011	CcSEcCtD
L-DOPA—Nausea—Dexamethasone—psoriatic arthritis	0.00105	0.0011	CcSEcCtD
L-DOPA—Urticaria—Methotrexate—psoriatic arthritis	0.00102	0.00107	CcSEcCtD
L-DOPA—Dizziness—Prednisone—psoriatic arthritis	0.00102	0.00106	CcSEcCtD
L-DOPA—Abdominal pain—Methotrexate—psoriatic arthritis	0.00102	0.00106	CcSEcCtD
L-DOPA—Vomiting—Prednisone—psoriatic arthritis	0.000979	0.00102	CcSEcCtD
L-DOPA—Rash—Prednisone—psoriatic arthritis	0.000971	0.00101	CcSEcCtD
L-DOPA—Dermatitis—Prednisone—psoriatic arthritis	0.00097	0.00101	CcSEcCtD
L-DOPA—Headache—Prednisone—psoriatic arthritis	0.000965	0.00101	CcSEcCtD
L-DOPA—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000948	0.000989	CcSEcCtD
L-DOPA—Asthenia—Methotrexate—psoriatic arthritis	0.000923	0.000963	CcSEcCtD
L-DOPA—Nausea—Prednisone—psoriatic arthritis	0.000915	0.000954	CcSEcCtD
L-DOPA—Pruritus—Methotrexate—psoriatic arthritis	0.000911	0.000949	CcSEcCtD
L-DOPA—Diarrhoea—Methotrexate—psoriatic arthritis	0.000881	0.000918	CcSEcCtD
L-DOPA—Dizziness—Methotrexate—psoriatic arthritis	0.000851	0.000887	CcSEcCtD
L-DOPA—Vomiting—Methotrexate—psoriatic arthritis	0.000818	0.000853	CcSEcCtD
L-DOPA—Rash—Methotrexate—psoriatic arthritis	0.000811	0.000846	CcSEcCtD
L-DOPA—Dermatitis—Methotrexate—psoriatic arthritis	0.000811	0.000845	CcSEcCtD
L-DOPA—Headache—Methotrexate—psoriatic arthritis	0.000806	0.000841	CcSEcCtD
L-DOPA—Nausea—Methotrexate—psoriatic arthritis	0.000764	0.000797	CcSEcCtD
